Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2044-5385
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX ; volume:10 ; number:11 ; day:3 ; month:11 ; year:2020 ; pages:1-10 ; date:11.2020
Blood cancer journal ; 10, Heft 11 (3.11.2020), 1-10, 11.2020
- Urheber
-
Kaufman, Jonathan L.
Dimopoulos, Meletios A.
White, Darrell
Benboubker, Lotfi
Cook, Gordon
Leiba, Merav
Morton, James
Joy Ho, P.
Kim, Kihyun
Takezako, Naoki
Moreau, Philippe
Sutherland, Heather J.
Magen, Hila
Iida, Shinsuke
Kim, Jin Seok
Miles Prince, H.
Cochrane, Tara
Oriol, Albert
Bahlis, Nizar J.
Chari, Ajai
O’Rourke, Lisa
Trivedi, Sonali
Casneuf, Tineke
Krevvata, Maria
Ukropec, Jon
Kobos, Rachel
Avet-Loiseau, Hervé
Usmani, Saad Z.
San-Miguel, Jesús F.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41408-020-00375-2
- URN
-
urn:nbn:de:101:1-2020121719562349631211
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:23 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Kaufman, Jonathan L.
- Dimopoulos, Meletios A.
- White, Darrell
- Benboubker, Lotfi
- Cook, Gordon
- Leiba, Merav
- Morton, James
- Joy Ho, P.
- Kim, Kihyun
- Takezako, Naoki
- Moreau, Philippe
- Sutherland, Heather J.
- Magen, Hila
- Iida, Shinsuke
- Kim, Jin Seok
- Miles Prince, H.
- Cochrane, Tara
- Oriol, Albert
- Bahlis, Nizar J.
- Chari, Ajai
- O’Rourke, Lisa
- Trivedi, Sonali
- Casneuf, Tineke
- Krevvata, Maria
- Ukropec, Jon
- Kobos, Rachel
- Avet-Loiseau, Hervé
- Usmani, Saad Z.
- San-Miguel, Jesús F.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Cost-effectiveness and budget impact analysis of Daratumumab, Lenalidomide and dexamethasone for relapsed-refractory multiple myeloma
Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: subgroup analyses of the phase 3 POLLUX study
Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment
Daratumumab Plus Carfilzomib: An Optimistic Approach in Relapsed/Refractory Multiple Myeloma
Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory multiple myeloma
Daratumumab
Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients – real world evidence analysis
Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk
Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease
Expanded natural killer cells potentiate the antimyeloma activity of daratumumab, lenalidomide, and dexamethasone in a myeloma xenograft model
Complete Remission in a TEMPI Syndrome Treated with a Daratumumab, Lenalidomide, and Dexamethasone-Based Regimen: A Case Report
The clinical efficacy of a daratumumab-based regimen in relapsed/refractory acute leukemia: a single-center experience
Cost-effectiveness and budget impact analysis of Daratumumab, Lenalidomide and dexamethasone for relapsed-refractory multiple myeloma
Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: subgroup analyses of the phase 3 POLLUX study
Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment
Daratumumab Plus Carfilzomib: An Optimistic Approach in Relapsed/Refractory Multiple Myeloma
Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory multiple myeloma
Daratumumab
Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients – real world evidence analysis
Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk
Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease
Expanded natural killer cells potentiate the antimyeloma activity of daratumumab, lenalidomide, and dexamethasone in a myeloma xenograft model
Complete Remission in a TEMPI Syndrome Treated with a Daratumumab, Lenalidomide, and Dexamethasone-Based Regimen: A Case Report
The clinical efficacy of a daratumumab-based regimen in relapsed/refractory acute leukemia: a single-center experience
Cost-effectiveness and budget impact analysis of Daratumumab, Lenalidomide and dexamethasone for relapsed-refractory multiple myeloma
Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: subgroup analyses of the phase 3 POLLUX study
Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment
Daratumumab Plus Carfilzomib: An Optimistic Approach in Relapsed/Refractory Multiple Myeloma
Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory multiple myeloma
Daratumumab
Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients – real world evidence analysis
Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk
Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease
Expanded natural killer cells potentiate the antimyeloma activity of daratumumab, lenalidomide, and dexamethasone in a myeloma xenograft model
Complete Remission in a TEMPI Syndrome Treated with a Daratumumab, Lenalidomide, and Dexamethasone-Based Regimen: A Case Report